TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29328779

Group type: EXPERIMENTAL
Intervention: Coordinated Specialty Care (CSC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual treatment settings
Number of subjects: 0
Study: 26881303

Group type: EXPERIMENTAL
Intervention: Chronic pain interventions (specific interventions not detailed in the abstract)
Number of subjects: 188
Study: 24904204

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) applied for 30 minutes once a day for 60 days.
Number of subjects: 61

Group type: COMPARATOR
Intervention: Basic therapy (control group).
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS).
Number of subjects: 61
Study: 22980307

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 102

Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 102
Study: 20195181

Group type: EXPERIMENTAL
Intervention: Intense interval training (INT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Prolonged running
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 36
Study: 17272968

Group type: EXPERIMENTAL
Intervention: Prosigne
Number of subjects: 26

Group type: COMPARATOR
Intervention: Botox
Number of subjects: 26
Study: 16033938

Group type: EXPERIMENTAL
Intervention: No delay in roll perturbation
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Short 50-ms delay in roll perturbation
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Long 150-ms delay in roll perturbation
Number of subjects: 19
Study: 12374440

Group type: EXPERIMENTAL
Intervention: Positive role models for promotion-focused individuals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative role models for prevention-focused individuals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Goal-incongruent role models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Goal-congruent role models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Real-life role models matching chronic goals
Number of subjects: 0
Study: 9935020

Group type: EXPERIMENTAL
Intervention: Captopril 6.25 mg increasing to 50 mg t.d.s. after intravenous streptokinase
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Captopril in anterior infarction with TIMI 0-2 flow
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Captopril in anterior infarction with corrected TIMI frame counts > 27
Number of subjects: 493

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 493
Study: 7561799

Group type: EXPERIMENTAL
Intervention: Oral brivudin (125 mg tablet every 6 hours for 5 days)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Intravenous acyclovir (10 mg/kg infused over 1 hour every 8 hours for 5 days)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Oral brivudin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Intravenous acyclovir
Number of subjects: 48
Study: 2222030

Group type: EXPERIMENTAL
Intervention: Percutaneous needle aspiration with drugs (metronidazole, diloxanide, chloroquine)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Drugs alone (metronidazole, diloxanide, chloroquine)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Percutaneous needle aspiration
Number of subjects: 36

Group type: COMPARATOR
Intervention: Drugs alone (non-aspirated group)
Number of subjects: 36
Study: 319319

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 4200

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 4200
Study: 31285082

Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m2, carboplatin AUC 6 mg/mL/min, and bevacizumab 15 mg/kg every 21 days until disease progression, complete remission, or limiting toxicity.
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Paclitaxel, carboplatin, and bevacizumab treatment
Number of subjects: 34
Study: 29195602

Group type: EXPERIMENTAL
Intervention: Erythrocytapheresis (treatment group)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Sham treatment by plasmapheresis (control group)
Number of subjects: 104
Study: 25644578

Group type: EXPERIMENTAL
Intervention: 0.20 ml local anaesthetic per mm² cross-sectional nerve area (starting volume)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.02 ml.mm(‐2) reduction in local anaesthetic volume if surgical anaesthesia was adequate
Number of subjects: 0
Study: 24381278

Group type: EXPERIMENTAL
Intervention: Congenitally blind participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sighted participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: fMRI analysis in both groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neural similarity matrices of IT and OSC
Number of subjects: 0
Study: 21647577

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (AMP) 10 mg and 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Δ(9)-tetrahydrocannabinol (THC) 7.5 mg and 15 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19512873

Group type: EXPERIMENTAL
Intervention: Sugammadex (4 mg/kg)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 52

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 52
Study: 17449580

Group type: EXPERIMENTAL
Intervention: 3.2 g/d CLA
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 6.4 g/d CLA
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (8 g safflower oil/d)
Number of subjects: 48
Study: 14730384

Group type: EXPERIMENTAL
Intervention: MnDPDP-enhanced MRI
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Unenhanced MRI
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Spiral CT
Number of subjects: 44
Study: 15335109

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 9000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9000
Study: 11681160

Group type: EXPERIMENTAL
Intervention: International Classification of Primary Care (ICPC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Read Clinical Codes, version II
Number of subjects: 0
Study: 9655716

Group type: EXPERIMENTAL
Intervention: HEPA air cleaner
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo air cleaner
Number of subjects: 35
Study: 8186134

Group type: EXPERIMENTAL
Intervention: Terbinafine 1% cream applied twice daily for 1 week
Number of subjects: 211

Group type: COMPARATOR
Intervention: Clotrimazole 1% cream applied twice daily for 4 weeks
Number of subjects: 211
Study: 3130124

Group type: EXPERIMENTAL
Intervention: Polaroid prints from a non-mydriatic fundus camera
Number of subjects: 127

Group type: COMPARATOR
Intervention: 35 mm transparencies
Number of subjects: 127

Group type: COMPARATOR
Intervention: Fluorescein angiograms
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Polaroid prints and 35 mm transparencies of equivalent quality
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Polaroid prints
Number of subjects: 127
Study: 29068831

Group type: EXPERIMENTAL
Intervention: Balanced colloid solution
Number of subjects: 160

Group type: COMPARATOR
Intervention: Balanced crystalloid solution
Number of subjects: 160
Study: 27979752

Group type: EXPERIMENTAL
Intervention: Competence, autonomy, and relatedness interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 26630142

Group type: EXPERIMENTAL
Intervention: Supportive care plus immunosuppressive therapy (immunosuppression group) for 3 years
Number of subjects: 162

Group type: COMPARATOR
Intervention: Supportive care alone (supportive-care group) for 3 years
Number of subjects: 162
Study: 23137271

Group type: EXPERIMENTAL
Intervention: 5% NaOCl
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 20
Study: 21631622

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 75
Study: 18056742

Group type: EXPERIMENTAL
Intervention: Topical NSAIDs
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral NSAIDs
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: General decision making
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Adverse effects
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Overall adherence and efficacy
Number of subjects: 30
Study: 16609086

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE) 0.625 mg/d
Number of subjects: 10739

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10739
Study: 12704534

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate foam 0.05%
Number of subjects: 279

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study: 11119091

Group type: EXPERIMENTAL
Intervention: Bladder infusion before trial of voiding (ToV)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard catheter removal
Number of subjects: 75
Study: 8814495

Group type: EXPERIMENTAL
Intervention: Erythropoietin therapy (45‐60 U/kg, three times a week)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (haemodialysis patients without erythropoietin treatment)
Number of subjects: 13
Study: 1415040

Group type: EXPERIMENTAL
Intervention: Whole-cell pertussis-component diphtheria-tetanus-pertussis vaccine (DTP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Acellular pertussis-component diphtheria-tetanus-pertussis vaccine (APDT)
Number of subjects: 40
Study: 4012381

Group type: EXPERIMENTAL
Intervention: Formula diet (Ensure)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-residue, clear-liquid diet
Number of subjects: 0
Study: 31868914

Group type: EXPERIMENTAL
Intervention: Vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 31451349

Group type: EXPERIMENTAL
Intervention: Arthroscopic Repair Group (ARG)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Open Repair Group (ORG)
Number of subjects: 52
Study: 29661413

Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine (1 μg kg-1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine via atomiser (1 μg kg-1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine by drops (1 μg kg-1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intranasal dexmedetomidine (both atomisation and drops)
Number of subjects: 0
Study: 27923390

Group type: EXPERIMENTAL
Intervention: Early use of ≥64-slice CTCA as part of routine assessment
Number of subjects: 2424

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 2424
Study: 24691606

Group type: EXPERIMENTAL
Intervention: 5 mg of tadalafil daily for 24 weeks
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo for 24 weeks
Number of subjects: 242
Study: 21962458

Group type: EXPERIMENTAL
Intervention: Cylinder cast immobilisation for four weeks followed by rehabilitation
Number of subjects: 8

Group type: COMPARATOR
Intervention: No immobilisation and early rehabilitation
Number of subjects: 8
Study: 19332493

Group type: EXPERIMENTAL
Intervention: High-fat overfeeding (60% energy, +50% for 5 days)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: High-fat overfeeding
Number of subjects: 26
Study: 17764785

Group type: EXPERIMENTAL
Intervention: Boussignac CPAP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bilevel PAP
Number of subjects: 0
Study: 14711459

Group type: EXPERIMENTAL
Intervention: Chicken extract (CE) group, 70 mL/bottle, three times a day, providing 18 g protein from the 37th week of pregnancy to 3 days postpartum.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group, high protein supplement was restricted.
Number of subjects: 30
Study: 12486650

Group type: EXPERIMENTAL
Intervention: Remifentanil-clonidine-propofol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sufentanil-propofol
Number of subjects: 0
Study: 10423058

Group type: EXPERIMENTAL
Intervention: 0.1 M HCl perfusion in GERD patients
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Successful therapy (omeprazole or fundoplication)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Acid perfusion
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Medical and surgical therapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Saline perfusion
Number of subjects: 48
Study: 8989404

Group type: EXPERIMENTAL
Intervention: Tendon vibration at 20 Hz
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tendon vibration at 30 Hz
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tendon vibration at 40 Hz
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tendon vibration starting at movement onset (40 Hz)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tendon vibration starting 5 s before movement onset and continuing throughout movement (40 Hz)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tendon vibration starting 5 s before movement onset and stopping at movement onset (40 Hz)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tendon vibration at 20 Hz (matching tasks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tendon vibration at 40 Hz (matching tasks)
Number of subjects: 0
Study: 2160441

Group type: EXPERIMENTAL
Intervention: VLCD with dietary fibre (30 g/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: VLCD without dietary fibre
Number of subjects: 22
Study: 7031568

Group type: EXPERIMENTAL
Intervention: Heparin prophylaxis (5,000 micro sodium heparin subcutaneously every 12 hours)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no heparin prophylaxis)
Number of subjects: 32
Study: 6437372

Group type: EXPERIMENTAL
Intervention: MOD‐TPN (15% dextrose, fat, and 5% amino acids)
Number of subjects: 88

Group type: COMPARATOR
Intervention: CON‐TPN (25% dextrose and 4.25% amino acids)
Number of subjects: 88
Study: 29294154

Group type: EXPERIMENTAL
Intervention: Type A biliary strictures
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Type B biliary strictures
Number of subjects: 65

Group type: COMPARATOR
Intervention: Comparison of Type A and Type B biliary strictures
Number of subjects: 65
Study: 26719058

Group type: EXPERIMENTAL
Intervention: mIPV2HD
Number of subjects: 233

Group type: COMPARATOR
Intervention: IPV
Number of subjects: 233
Study: 23098260

Group type: EXPERIMENTAL
Intervention: Working memory training (non-numerical)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Working memory training (numerical)
Number of subjects: 51

Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 51
Study: 22234648

Group type: EXPERIMENTAL
Intervention: Twice-a-week supervised aerobic and resistance training plus exercise counselling (exercise group)
Number of subjects: 606

Group type: COMPARATOR
Intervention: Counselling alone (control group)
Number of subjects: 606
Study: 20138446

Group type: EXPERIMENTAL
Intervention: Iron intake of 1.11 mg/kg/day (SD 0.06)
Number of subjects: 13
Study: 18307851

Group type: EXPERIMENTAL
Intervention: Cough duration
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: Children
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: History of fever
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: Restricted activities
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: More severe symptoms
Number of subjects: 807
Study: 14760090

Group type: EXPERIMENTAL
Intervention: gp100209-2M peptide immunization
Number of subjects: 35
Study: 11499321

Group type: EXPERIMENTAL
Intervention: P‐1 medium (Irvine Scientific)
Number of subjects: 182

Group type: COMPARATOR
Intervention: IVF‐50 medium (Scandinavian IVF Science)
Number of subjects: 182
Study: 9258614

Group type: EXPERIMENTAL
Intervention: Brush cytology
Number of subjects: 63

Group type: COMPARATOR
Intervention: Impression cytology
Number of subjects: 63
Study: 7942250

Group type: EXPERIMENTAL
Intervention: Alcohol administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tonic water administration (placebo)
Number of subjects: 0
Study: 3284831

Group type: EXPERIMENTAL
Intervention: 6 mg piretanide once or twice daily
Number of subjects: 47

Group type: COMPARATOR
Intervention: 50 mg hydrochlorothiazide plus 5 mg amiloride
Number of subjects: 47
Study: 29971702

Group type: EXPERIMENTAL
Intervention: Biofeedback training with HeartMath monitor and Quick Coherence technique
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Relaxation training with HeartMath Quick Coherence technique
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 44
Study: 26742065

Group type: EXPERIMENTAL
Intervention: Diet and physical activity intervention
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 46
Study: 24498968

Group type: EXPERIMENTAL
Intervention: Enzyme-treated asparagus extract (ETAS) at 200 mg/kg body weight
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Enzyme-treated asparagus extract (ETAS) at 1000 mg/kg body weight
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Enzyme-treated asparagus extract (ETAS) at 150 mg/d for 7 days
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Enzyme-treated asparagus extract (ETAS) at 0.125 mg/mL
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Enzyme-treated asparagus extract (ETAS) at 1.0 mg/mL
Number of subjects: 1

Group type: COMPARATOR
Intervention: ETAS-untreated mice
Number of subjects: 1
Study: 22217936

Group type: EXPERIMENTAL
Intervention: Adenosine-guided ablation until dormant conduction is abolished
Number of subjects: 488

Group type: COMPARATOR
Intervention: Standard PVI
Number of subjects: 488
Study: 21198228

Group type: EXPERIMENTAL
Intervention: CBT4CBT (computer-based cognitive-behavioral therapy)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 77
Study: 18090049

Group type: EXPERIMENTAL
Intervention: nevirapine 400 mg once-daily (n = 31)
Number of subjects: 62

Group type: COMPARATOR
Intervention: nevirapine 200 mg twice-a-day (n = 31)
Number of subjects: 62
Study: 16120030

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Multiple daily insulin (MDI)
Number of subjects: 28
Study: 11898480

Group type: EXPERIMENTAL
Intervention: New antiepileptic drugs (AEDs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparative studies of AEDs
Number of subjects: 0
Study: 9923580

Group type: EXPERIMENTAL
Intervention: Grapefruit juice with 2 mg pranidipine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Orange juice with 2 mg pranidipine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Water with 2 mg pranidipine
Number of subjects: 16
Study: 8087824

Group type: EXPERIMENTAL
Intervention: Captopril (50-200 mg daily)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN; 5 and 15 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Combined therapy with captopril and ISDN
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control
Number of subjects: 11
Study: 2676430

Group type: EXPERIMENTAL
Intervention: Intranasal glucagon
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular glucagon
Number of subjects: 0
Study: 1103563

Group type: EXPERIMENTAL
Intervention: Diphenidol (1,1‐diphenyl‐4‐piperidino‐l‐butanol hydrochloride)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30508863

Group type: EXPERIMENTAL
Intervention: Acute exercise
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Chronic exercise
Number of subjects: 16

Group type: COMPARATOR
Intervention: Passive control group
Number of subjects: 16
Study: 28202885

Group type: EXPERIMENTAL
Intervention: Tolvaptan add-on therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional diuretic therapy
Number of subjects: 50
Study: 27550429

Group type: EXPERIMENTAL
Intervention: Timely intraoperative iodine irrigation (0.33% povidone-iodine)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control (no iodine irrigation)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Timely intraoperative iodine irrigation
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Timely iodine irrigation
Number of subjects: 99
Study: 25186156

Group type: EXPERIMENTAL
Intervention: Intervention group receiving calculated future fracture risk communicated to their GP with evidence-based recommendations.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving usual care.
Number of subjects: 0
Study: 22648554

Group type: EXPERIMENTAL
Intervention: Surgery with or without SMT
Number of subjects: 291

Group type: COMPARATOR
Intervention: SMT alone
Number of subjects: 291
Study: 19519891

Group type: EXPERIMENTAL
Intervention: Loss to follow-up (LTFU) participants had the event
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: None of the LTFU participants had the event
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All LTFU participants had the event
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All LTFU participants in the treatment group had the event; none in the control group (worst case scenario)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Event incidence among LTFU participants increased in the intervention group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Event incidence among LTFU participants decreased in the control group
Number of subjects: 0
Study: 17900783

Group type: EXPERIMENTAL
Intervention: Chitosan-containing gum chewing
Number of subjects: 12

Group type: COMPARATOR
Intervention: Chitosan mouth rinse solution
Number of subjects: 12
Study: 15120509

Group type: EXPERIMENTAL
Intervention: Polylactide (PLA) barrier membranes during guided tissue regeneration (test)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional flap surgery (control)
Number of subjects: 10
Study: 11786768

Group type: EXPERIMENTAL
Intervention: Colonic J-pouch
Number of subjects: 12

Group type: COMPARATOR
Intervention: Straight group
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Colonic J-pouch and Straight group
Number of subjects: 12
Study: 10204813

Group type: EXPERIMENTAL
Intervention: 40 mg controlled‐release nifedipine once daily
Number of subjects: 22

Group type: COMPARATOR
Intervention: 20 mg sustained‐release nifedipine twice daily
Number of subjects: 22
Study: 8646573

Group type: EXPERIMENTAL
Intervention: Yellow dye laser (580 nm)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Red dye laser (630 nm)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Both yellow and red dye lasers
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Dye laser treatment
Number of subjects: 210
Study: 2140929

Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100